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ACR = American College of Rheumatology; AE = adverse event; CTLA4–Ig = cytotoxic T lymphocyte-associated antigen 4–IgG1; DMARD =
disease-modifying antirheumatic drug; HAQ = Health Assessment Questionnaire; IL = interleukin; RA = rheumatoid arthritis; SF-36 = Short Form
36-Item Health Survey; TNF = tumor necrosis factor.
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Abstract
Until the pathophysiology/etiology of rheumatoid arthritis (RA) is
better understood, treatment strategies must focus on disease
management. Early diagnosis and treatment with disease-modifying
antirheumatic drugs (DMARDs) are necessary to reduce early joint
damage, functional loss, and mortality. Several clinical trials have
now clearly shown that administering appropriate DMARDs early
yields better therapeutic outcomes. However, RA is a hetero-
geneous disease in which responses to treatment vary considerably
for any given patient. Thus, choosing which patients receive
combination DMARDs, and which combinations, remains one of
our major challenges in treating RA patients. In many well
controlled clinical trials methotrexate and other DMARDs, including
the tumor necrosis factor-α inhibitors, have shown considerable
efficacy in controlling the inflammatory process, but many patients
continue to have active disease. Optimizing clinical response
requires the use of a full spectrum of clinical agents with different
therapeutic targets. Newer therapies, such as rituximab, that
specifically target B cells have emerged as viable treatment
options for patients with RA.
Introduction
Current treatment guidelines suggest that early diagnosis and
initial treatment with disease-modifying antirheumatic drugs
(DMARDs) are necessary to limit early joint damage and
functional loss and to reduce mortality associated with
rheumatoid arthritis (RA) [1]. The earlier use of methotrexate
alone and in combination with other DMARDs is now the
standard of care and has yielded better outcomes for patients
with RA.
However, RA is a heterogeneous disease, and patient
responses to standard treatments are variable. Most recent
clinical trials of newer DMARDs alone and in combination
with methotrexate have shown that ACR50 response – which
includes reducing the signs and symptoms of disease by
50%, according to criteria established by the American
College of Rheumatology (ACR) – was achieved in less than
two-thirds of the patients [2-5]. That leaves at least one-third
of the most seriously affected patients with RA without an
effective long-term treatment strategy. Until we are able to
identify which patients will respond to which treatment, the
availability of a variety of agents with different therapeutic
targets offers the best opportunity to optimize clinical
outcomes.
Rituximab, a chimeric anti-CD20 monoclonal antibody that
has emerged as a potential treatment for RA via selective
targeting of B lymphocytes, has been used extensively in the
treatment of B cell malignancies. There is a growing body of
evidence for the pathophysiologic role of B cells. Silverman
and Carson [6] described that B lymphocytes can present
immune-complexed antigens to autoreactive T cells; express
adhesion and other co-stimulatory molecules that promote
T cell activation; synthesize chemokines that induce leukocyte
infiltration; produce factors that initiate and sustain
angiogenesis and granulation tissue formation; and release
autoantibodies that are directly or indirectly destructive to
tissues and maintain a memory response to autoantigens.
Apart from B cells and T cells, populations of monocytes,
macrophages, endothelial cells, and fibroblasts have been
implicated in the ongoing inflammatory process [7]. The
availability of a broader spectrum of agents with different
targeting mechanisms will provide more effective treatment
options for diverse patient populations.
Overall picture of rheumatoid arthritis
RA affects almost 1% of the adult population worldwide [1].
Clinicians have reason to be concerned when they manage a
chronic and debilitating condition that requires aggressive,
life-long management. When one looks at large cohort
populations, patients with RA exhibit increased morbidity and
mortality, compounded by a dramatic impact on quality of life.
Approximately 80% of affected patients are disabled after
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20 years [8], and life expectancy is reduced by an average of
3–18 years [9].
The management of RA has a marked impact in terms not
only of the financial burden to the health care system but also
of the financial burden to individual patients and their families.
It has been estimated that the disorder costs the average
individual up to US$8500 annually [10], with time lost from
work ranging from 2.7 to 30 days [11].
Treatment advances over the past decade
During the past 10 years or so, advances in the treatment of
RA have underscored the role of methotrexate as a major
cornerstone of therapy. However, many randomized controlled
trials have demonstrated that methotrexate in combination
with another DMARD is more effective than methotrexate
monotherapy for many patient populations [3-5,12].
In a 2002 study, Kremer and colleagues [12] tested the
hypothesis that adding leflumonide to the regimen of patients
taking methotrexate alone would strengthen the clinical
response. The team assigned 263 patients with RA to
leflunomide plus methotrexate or methotrexate alone. At
24 weeks, 46.2% (60 of 130) of patients receiving the
leflunomide–methotrexate combination had achieved an
ACR20 clinical response, as compared with 19.5% of the
patients who had been maintained on a methotrexate–
placebo regimen (P < 0.001). In addition, they reported that
26.2% of the leflunomide patients achieved an ACR50
response, as compared with 6.0% of the patients in the
methotrexate–placebo arm (P < 0.001). This study was one
of the first to show that the combination of the two biologic
agents produced statistically significant and clinically
meaningful improvement in patients with active RA.
In a 2-year, randomized, double-blind, placebo-controlled trial,
O’Dell and colleagues [13] compared the effectiveness of
methotrexate in combination with either hydroxychloroquine
or sulfasalazine, as well as a combination of all three drugs.
After 2 years, 55% of the 58 patients in the triple therapy arm
achieved an ACR50 response; 40% of patients on
hydroxychloroquine and methotrexate achieved an ACR50
response; and 29% of those on sulfasalazine and metho-
trexate achieved an ACR50 response. The differences
between triple therapy and double therapy with sulfasalazine
reached statistical significance (P = 0.005).
Biologic response modifiers
Efforts to develop safer and more effective treatments for RA,
based on an improved understanding of the role of
inflammatory mediators, have been realized through the
development of the biologic response modifiers. Some
biologics have been approved for use in RA by the US Food
and Drug Administration and the European Medicine
Evaluation Agency, including etanercept (a soluble tumor
necrosis factor [TNF]-α type II receptor–IgG1 fusion protein
administered subcutaneously), infliximab (a chimeric [human
and mouse] monoclonal antibody against TNF-α), and
adalimumab (a human anti-TNF monoclonal antibody). These
therapies have shown the ability to change dramatically the
outcomes of the disease in some RA patients.
Researchers have observed that interleukin (IL)-1, IL-6, and
TNF-α are important mediators that initiate and maintain
inflammation in RA, resulting in cellular infiltration of synovium
and damage, and the destruction of cartilage and bone [14].
TNF-α, a potent cytokine that exerts diverse stimulatory
effects, is produced mainly by monocytes and macrophages,
but also by B cells, T cells, and fibroblasts.Newly synthesized
TNF-α is expressed on the cell membrane and subsequently
released through the cleavage of its membrane-anchoring
domain by a serine metalloproteinase. Thus, inhibition of
TNF-α secretion may represent a therapeutic target.
RA is believed to be initiated by CD4+ T cells, which amplify
the immune response by stimulating other mononuclear cells,
synovial fibroblasts, chondrocytes, and osteoclasts. Activated
CD4+ T cells contribute to stimulation of osteoclastogenesis
and activation of metalloproteinases responsible for the
degradation of connective tissue, resulting in joint damage.
Clearly, there are many possible therapeutic targets, but
inhibition of cytokines appears to offer an especially efficient
approach to suppressing inflammation and preventing joint
damage [14]. There are four biological therapies currently
approved for RA: three TNF-α inhibitors (infliximab,
etanercept, and adalimumab) and one IL-1 inhibitor (anakinra).
Abatacept, a cytotoxic T lymphocyte-associated antigen
4–IgG1 (CTLA4–Ig) fusion protein, known as a co-stimulation
blocker, is administered in a 30 min infusion. Recent clinical
trial data show that the combination of abatacept and
methotrexate improves the signs and symptoms, physical
functioning, and quality of life of patients with active RA [15].
Etanercept
In the Trial of Etanercept and Methotrexate with Radiographic
Patient Outcomes (TEMPO), Klareskog and coworkers [16]
enrolled 685 patients with active RA in a double-blind,
randomized trial to determine the safety and efficacy of
treatment with etanercept or methotrexate alone or in
combination versus placebo for up to 52 weeks. Patients
were randomly assigned to treatment with etanercept 25 mg
subcutaneously twice a week, oral methotrexate monotherapy
up to 20 mg every week, or a combination of the two agents.
The researchers found that the proportions of patients
achieving ACR50 and ACR70 responses were consistently
higher for the combination group than either the etanercept
or methotrexate treatment arms throughout the study (Fig. 1).
At week 52, 69% of the patients in the combination protocol
achieved an ACR50 response, as compared with 43% andS4
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48% in the methotrexate and etanercept monotherapy
groups, respectively (P < 0.0001). Moreover, after a 1-year
period, 43% of the patients in the combination group had an
ACR70 response, as compared with 19% and 24% in the
methotrexate and etanercept monotherapy patients,
respectively (P < 0.0001). Additionally, more than one-third of
patients treated with the methotrexate–etanercept combination
protocol were in remission at 52 weeks.
The number of patients reporting infection or adverse events
(AEs) was similar in all groups. Overall, Klareskog and
colleagues reported that the combination of etanercept and
methotrexate was significantly better in reducing disease
activity, improving functional disability, and retarding
radiographic progression compared with methotrexate or
etanercept alone.
A comparison of therapy with methotrexate and therapy with
etanercept was also conducted by Bathon and colleagues
[17]. They evaluated 632 patients with early RA who were
given either twice weekly subcutaneous etanercept (10 mg or
25 mg) or weekly oral methotrexate (mean 19 mg/week) for
12 months.
Compared with patients who received methotrexate, patients
taking the 25 mg dose of etanercept exhibited a more rapid
rate of improvement, with significantly more patients having
ACR20, ACR50, and ACR70 response improvement in
disease activity during the first 6 months (P < 0.05). The
mean increase in the erosion score during the first 6 months
was 0.30 in the group assigned to receive 25 mg etanercept
and 0.68 in the methotrexate group (P = 0.001). The
respective increases during the first 12 months were 0.47
and 1.03 (P = 0.002).
Among patients who received the 25 mg dose of etanercept,
72% had no increase in the erosion score, as compared with
60% of patients in the methotrexate group (P = 0.007). This
group of patients also had fewer AEs (P = 0.02) and fewer
infections (P = 0.006) than did the group treated with metho-
trexate. Compared with oral methotrexate, subcutaneous
etanercept acted more rapidly to decrease symptoms and
slow joint damage in patients with early active RA.
Bathon and colleagues observed that the patients in the
study were at risk for rapidly progressive joint damage. Their
disease was predicted to progress without treatment at an
estimated rate of four to five points per year on the Sharp
erosion subscale, and four points per year on the Sharp joint-
space narrowing subscale. The rates of progression for joint-
space narrowing were low. Both etanercept and metho-
trexate prevented joint-space narrowing. The overall rates of
erosion were also low, equivalent to the occurrence of one
new erosion or the erosion of 20% of one joint every year in
the methotrexate group and every 2 years in the group
assigned to receive 25 mg etanercept. The effects of this
dose of etanercept were evident sooner than were the effects
of methotrexate, but the rates of change were similar in the
two groups during the latter half of the study. Over a 1-year
period, treatment with etanercept halted erosions in 72% of
patients, whereas treatment with methotrexate halted
erosions in 60% of patients [17].
Adalimumab
In a pivotal study [18], the combination of the biologic
adalimumab and methotrexate, particularly at a higher dose of
40 mg every other week, yielded a statistically significant
improvement compared with methotrexate plus placebo. In
that multicenter, 52-week, double-blind, placebo-controlled
study, 619 patients with active RA who had an inadequate
response to methotrexate alone were randomly assigned to
receive adalimumab 40 mg subcutaneously every other week
(n = 207), adalimumab 20 mg subcutaneously every week
(n = 212), or placebo (n = 200) plus concomitant treatment
with methotrexate. The primary efficacy end-points were
radiographic progression at week 52 (total Sharp score by a
modified method); clinical response at week 24, defined as
improvements that achieved at least an ACR20 response;
and improvement in physical function at week 52, based on
the disability index of the Health Assessment Questionnaire
(HAQ). At week 52 there was statistically significantly less
radiographic progression (Fig. 2), as measured by change in
total Sharp score, in the patients receiving adalimumab either
40 mg every other week (change [mean ± standard deviation]
0.1 ± 4.8) or 20 mg weekly (0.8 ± 4.9), as compared with
that in the placebo group (2.7 ± 6.8; P < 0.001).
At week 52, ACR50 responses were achieved by 42% and
38% of patients taking adalimumab 40 mg every other week
and 20 mg weekly, respectively, but by 10% of patients
taking placebo (P < 0.001). In terms of physical function at
Figure 1
Etanercept in active rheumatoid arthritis (TEMPO trial): ACR
responses at 52 weeks. *P < 0.01, ‡P < 0.0001, versus placebo;
†P < 0.05, §P < 0.0001, versus etanercept. ACR, American College of
Rheumatology; MTX, methotrexate; TEMPO, Trial of Etanercept and
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week 52, patients on combination therapy with adalimumab
and methotrexate experienced statistically significant improve-
ment (mean change in HAQ score –0.59 and –0.61,
respectively, versus –0.25; P < 0.001).
Adalimumab was generally well tolerated. Discontinuations
occurred in 22% of adalimumab treated patients and in 30%
of placebo treated patients. The rate of both serious AEs and
nonserious AEs was similar between adalimumab and
placebo groups. The proportion of patients reporting serious
infections was higher in patients receiving adalimumab
(3.8%) than in those receiving placebo (0.5%; P < 0.02) and
was highest in the patients receiving 40 mg every other week.
The benefits of early treatment of RA with adalimumab, either
alone or in combination with methotrexate, were supported
more recently by the results of the PREMIER study [19]. In an
analysis of almost 800 patients with a disease duration of
less than 3 years, adalimumab 40 mg every other week plus
methotrexate (escalated rapidly to 20 mg/week) exhibited
statistically significant improvement in ACR50 clinical
response and amelioration of disease progression compared
with either adalimumab or methotrexate alone. Of patients in
the combination therapy group, 61% and 46% achieved
ACR50 and ACR70 responses, respectively, as compared
with 46% and 28% in the methotrexate group (P < 0.001) –
a statistically significant difference that was sustained for up
to 2 years. The difference in clinical response was also
comparable between the combination arm of the trial and
patients taking adalimumab alone. Moreover, at 2 years
radiographic remission (as indicated by a Disease Activity
Scale [DAS28] score <2.6) was achieved by 50% of
patients receiving combination therapy.
Infliximab
Much of the recent knowledge regarding the safety and
efficacy of infliximab in combination with methotrexate
emerged from analysis of data from the Anti-Tumor Necrosis
Factor Trial in Rheumatoid Arthritis with Concomitant Therapy
(ATTRACT) trial [20,21], the pivotal study that led to approval
of the TNF-α inhibitor infliximab in the USA and worldwide.
ATTRACT demonstrated that the combination of metho-
trexate and infliximab, in particular, with highest doses given
every 4–8 weeks, resulted in better clinical responses than
methotrexate plus placebo.
In that study the investigators established that infliximab not
only provided significant improvements in physical function
and quality of life, but also succeeded in slowing or halting
progressive joint damage and signs and symptoms of RA in
patients who previously had an incomplete response to
methotrexate alone.
The study included 428 patients who were randomly
assigned to receive methotrexate plus placebo or infliximab at
a dose of 3 mg/kg or 10 mg/kg plus methotrexate for
54 weeks, with an additional year of follow up. The protocol
was later amended to allow for continued treatment during
the second year.
Of 259 patients who entered the second year of treatment,
216 continued to receive infliximab plus methotrexate for
102 weeks. Ninety-four of these 259 patients experienced a
gap in therapy of greater than 8 weeks before continuing
therapy. Infusions were administered at baseline, week 2, and
week 6, followed by treatment every 4 weeks or every 8
weeks – alternating with placebo infusions in the interim 4-
week visits – at a dose of 3 mg/kg or 10 mg/kg for a total of
102 weeks, which included the gap in therapy.
The results of the study showed that the infliximab plus
methotrexate regimens led to significantly greater improve-
ment in HAQ scores (P = 0.006) and in the Short Form 36-
Item Health Survey (SF-36) physical component summary
scores (P = 0.011), compared with the group of patients
receiving monotherapy with methotrexate. There also was
stability in the SF-36 mental component summary score
among patients who received the infliximab plus methotrexate
regimens. The median changes from baseline to week 102 in
the total radiographic score were 4.25 for patients who
received the methotrexate-only regimen and 0.50 for patients
who received the infliximab plus methotrexate regimen. The
proportion of patients achieving an ACR50 response at week
102 varied from 20% to 21% for the infliximab plus metho-
trexate groups, as compared with 6% for the methotrexate-
only group. These data emphasize that the combination of
infliximab plus methotrexate conferred significant, clinically
relevant improvement in physical function and quality of life,
accompanied by inhibition of progressive joint damage and
sustained improvement in the signs and symptoms of RA
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Figure 2
Adalimumab plus methotrexate in active rheumatoid arthritis: mean
change from baseline in total Sharp score. *P < 0.01, †P ≤ 0.001,
versus placebo. MTX, methotrexate. Reproduced with permission [18].
Copyright © 2004 by John Wiley & Sons, Inc.
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among patients who previously had an incomplete response
to methotrexate alone.
The ASPIRE (Active controlled Study of Patients receiving
Infliximab for RA of Early onset) trial [5] randomly assigned
patients with early RA to either methotrexate alone or
methotrexate plus 3 mg/kg or 6 mg/kg infliximab at weeks 0,
2, and 6, and every 8 weeks thereafter through week 46. It
revealed improvement in ACR scores in both combination
treatment groups compared with the methotrexate arm
(38.9% and 46.7%, versus 26.4%, respectively; P < 0.001
for both comparisons), significantly less radiographic
progression at 6 months and 12 months, and improvement in
physical function.
Anakinra
Treatment with anakinra, the first IL-1 receptor antagonist,
either alone or in combination with methotrexate, has
emerged as an effective medication for patients with
moderate-to-severe RA. In a study of 419 patients with active
RA of duration greater than 6 months but less than 12 years
[22], patients were randomly assigned to placebo or one of
five doses of anakinra (0.04, 0.1, 0.4, 1.0 or 2.0 mg/kg) plus
methotrexate. Those assigned to the five anakinra regimens
exhibited statistically significant (P = 0.001), dose-escalating
efficacy in ACR20 responses as compared with the placebo
plus methotrexate group after 12 weeks. The ACR20
response rates in the anakinra 1.0 mg/kg (46%; P = 0.001)
and 2.0 mg/kg (38%; P = 0.007) dose groups were
significantly better than those in the placebo group (19%).
ACR20 responses at 24 weeks were consistent with those at
12 weeks. Other researchers have reported similar 6-month
ACR20 (and ACR50) responses, as well as in individual
components (i.e. HAQ, pain, C-reactive protein level, and
erythrocyte sedimentation rate) [23].
Abatacept
Abatacept (CTLA4–Ig), a cytotoxic T-lymphocyte-associated
antigen 4–IgG1 fusion protein, is the first in a new class of
drugs known as co-stimulation blockers that are being
evaluated for the treatment of RA. Abatacept selectively
modulates the co-stimulatory signal required for full T cell
activation. The agent, which binds to CD80 and CD86 on
antigen-presenting cells, blocking the engagement of CD28
on T cells and thus preventing T cell activation, acts earlier in
the inflammatory cascade than do other biologic therapies by
directly inhibiting the activation of T cells and the secondary
activation of macrophages and B cells.
The efficacy of this novel therapy was tested by Kremer and
colleagues [24], who randomly assigned patients with active
RA despite methotrexate therapy to receive 2 mg/kg CTLA4–
Ig (105 patients), 10 mg/kg (115 patients), or placebo (119
patients) for 6 months. All patients also received methotrexate
therapy during the study. Patients treated with 10 mg
CTLA4–Ig were more likely to have an ACR20 response than
were patients who received placebo (60% versus 35%;
P < 0.001). Significantly higher rates of ACR50 and ACR70
responses were seen in both CTLA4–Ig groups than in the
placebo group [24]. The group given 10 mg CTLA4–Ig had
clinically meaningful and statistically significant improvements
in all eight subscales of the SF-36. CTLA4–Ig was well
tolerated, with an overall safety profile similar to that of
methotrexate [15].
Recently released phase III results from the Abatacept in
Inadequate responders to Methotrexate (AIM) trial [24] found
that 48.3% of patients achieved an ACR50 response after
1 year of therapy compared with 18.2% of patients who were
given methotrexate injections (P < 0.001). At 6 months, the
number of patients on abatacept who achieved an ACR70
response was 19.8%, compared with 6.5% of patients on
methotrexate. After 1 year, 28.8% of patients had reached an
ACR70 response, compared with 6.1% of patients on
methotrexate. Both differences were statistically significant
(P < 0.001).
Tumor necrosis factor-α α: potential safety
issues
Although researchers, scientists, and clinicians are
enthusiastic in their support of early intervention with TNF-α
inhibitors for patients with RA, safety issues remain an
important consideration. Although infusion reactions and
other AEs are infrequent, they may be very serious in some
patients, in particular when complications associated with
opportunistic infections occur. There is a need to follow
patients very closely and to work with primary care physicians
to see that these issues are addressed first and foremost.
Rare and serious AEs include infections (bacterial, fungal, or
tubercular), demyelination, infusion related events, hematologic/
lymphoproliferative disorders, drug-induced systemic lupus
erythematosus/vasculitis, hepatotoxicity (infliximab), and
potential congestive heart failure. The development of
neutralizing antibodies also can be an issue in some patients
and needs further exploration. Further studies are needed to
determine whether some of these reported side effects are
truly related to the TNF-α inhibitor, or are a consequence of
the disease itself and/or comorbid conditions and
concomitant medications.
Challenges
Typically, clinicians have reserved biologics for those patients
with severe disease who have failed other therapies. However,
the emerging body of evidence suggests that practitioners
should be moving toward treating earlier disease with these
biologic agents in an effort to prevent structural damage. In
addition, because of the costs associated with biologic therapy
– often more than US$1000 per month [25] – and the potential
risk for immune suppression, one of the key challenges that
clinicians should address when considering the use of TNF-α
inhibitor therapy for active RA is how to determine which
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patients should be receiving which agents and in what
combination. Importantly, the medical community must endeavor
to identify those patients who will respond over the long term to
these agents and weigh the risk/benefit. Is it possible to pick out
which patients are most likely to have that long-term response?
There are numerous challenges and opportunities, as well as
many unmet needs for patients with RA.
Conclusion
RA is a hetereogeneous disease; there is substantial
evidence that some patients respond adequately to a single
DMARD, whereas others require a combination regimen.
Reliable predictors of response are needed to guide
therapeutic decision making, along with a firm definition of
therapeutic goals. It is of equal importance to arrest the
ongoing pre-existing damage or to intervene earlier to prevent
damage. In addition, over the long term, as research and
treatment become more aggressive, efficacy, toxicity, and
costs must be balanced within the therapeutic equation to
enhance the quality of life in patients with RA (Table 1).
The next generation of therapies for RA will provide
considerable opportunities. These include next generation
TNF-α inhibitors, anticytokines (anti-IL-6 receptor, anti-IL-15,
and anti-IL-1), angiogenesis inhibitors, antiadhesion molecules,
anti-T-cell co-stimulatory blockers (e.g. abatacept), anti-B-cell
therapies (i.e. rituximab and belimumab), and many others.
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